In the HARMONY Alliance Study of European randomized clinical trials, researchers sought to determine if MRD could serve as an intermediate endpoint in intensively treated AML.

Kura Oncology Inc. (NASDAQ:KURA) is one of the stocks that will double in 2026. On November 24, Barclays analyst Etzer Darout raised the firm’s price target on Kura Oncology to $28 from $11 and ...

A new portable ultrasound machine has been installed at the Eric and Marion Scott Chemotherapy Unit at Noble’s Hospital, ...

The pandemic phoneline system has been expanded to include two nurses per service across 26 hospitals in Ireland ...

The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2 -mutated ...

A new study published in the Journal of American Medical Association showed that reduced right ventricular ejection fraction ...

Nearly one-third of families of children receiving chemotherapy for acute lymphoblastic leukemia (ALL) develop serious ...

Treatment with glucagon-like peptide-1 receptor agonists was associated with lower probabilities of heart, kidney, and lung complications after partial nephrectomy for RCC.

The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...

AFSOS 2025 introduced the first European reference for photobiomodulation, outlining the evidence, dosing, and clinical use in supportive cancer care.

Siddhartha Mukherjee, oncologist and author of “The Emperor of All Maladies,” asks: What if we change what a tumor can eat?

The $2.25bn Coomera Hospital will take at least another five years to be built, with the expanded facility expected to be ...